Osteoporosis Postmenopausal
📧 Sign up to get email alerts when something new happens for Osteoporosis Postmenopausal.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Kauliv (teriparatide) — Strides Pharma (Cyprus) Limited
Kauliv (teriparatide) has been authorised by the EMA for osteoporosis-related indications, including postmenopausal osteoporosis, by Strides…
-
EMA approval · 2026-08-24EMA Authorised: Izamby (denosumab) — Mabxience Research SL
EMA authorises Izamby (denosumab) for bone resorption disorders including osteoporosis and postmenopausal osteoporosis.
-
EMA approval · 2026-08-20EMA Authorised: Junod (denosumab) — Gedeon Richter Plc.
Authorisation of Junod (denosumab) by Gedeon Richter Plc. for conditions related to bone resorption and osteoporosis, including postmenopaus…
-
EMA approval · 2026-08-19EMA Authorised: Prolia (denosumab) — Amgen Europe B.V.
EMA authorises Prolia (denosumab) for osteoporosis-related indications, confirming market approval in the European Union.
-
EMA approval · 2026-08-18EMA Authorised: Conexxence (denosumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Conexxence (denosumab) for osteoporosis indications, including postmenopausal osteoporosis and bone resorption conditions.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-07-17EMA Authorised: Kefdensis (denosumab) — Stada Arzneimittel AG
The EMA has authorised Kefdensis (denosumab) by Stada Arzneimittel AG for conditions related to bone resorption and osteoporosis, including …
-
EMA approval · 2026-07-14EMA Authorised: Acvybra (denosumab) — Reddy Holding GmbH
EMA authorised Acvybra (denosumab) for osteoporosis-related indications in Europe, with Reddy Holding GmbH as MAH.
-
EMA approval · 2026-06-16EMA Authorised: Kefdensis (denosumab) — Stada Arzneimittel AG
Authorised status for Kefdensis (denosumab) by Stada Arzneimittel AG for bone resorption disorders including osteoporosis and postmenopausal…
-
EMA approval · 2026-02-20EMA Authorised: Osqay (denosumab) — Theramex Ireland Limited
EMA has authorised Osqay (denosumab) by Theramex Ireland Limited for a bone resorption indication, marking approval in the European Union.
-
EMA approval · 2024-11-25EMA Authorised: Kauliv (teriparatide) — Strides Pharma (Cyprus) Limited
The EMA has authorized Kauliv, a teriparatide-containing medicine by Strides Pharma (Cyprus) Limited, for osteoporosis and postmenopausal os…
-
EMA approval · 2024-08-28EMA Authorised: Ibandronic Acid Teva (ibandronic acid) — Teva Pharma B.V.
EMA authorised Teva's ibandronic acid with indications including postmenopausal osteoporosis, breast neoplasms, neoplasm metastasis, and bon…
-
CLINICAL_TRIALS trial_result · 2022-02-03Clinical Trial Update: A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED) [Phase 3]
Phase 3 trial comparing alendronate with and without calcium versus calcium alone in postmenopausal osteoporosis has completed.
-
CLINICAL_TRIALS trial_result · 2021-10-15Clinical Trial Update: Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption [Phase 3]
Phase 3 trial update assessing early effects of abaloparatide on tissue-based indices of bone formation and resorption in osteoporosis, with…
-
EMA withdrawal · 2018-12-12EMA Withdrawn: Zoledronic acid Teva Pharma (zoledronic acid) — Teva B.V.
EMA withdrew zoledronic acid Teva Pharma (zoledronic acid) from the market in 2018 for indications including osteoporosis, osteitis deforman…
-
FDA approval · 2018-06-27FDA Approved: EVISTA — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for EVISTA (raloxifene hydrochloride) by Eli Lilly. The action updates the labeling with a new o…
-
FDA approval · 2016-04-08FDA Approved: RALOXIFENE HYDROCHLORIDE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved the original application for raloxifene hydrochloride (Amneal Pharmaceuticals LLC) as a generic, for postmenopausal osteoporosi…
-
CLINICAL_TRIALS trial_result · 2011-01-11Clinical Trial Update: OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women [Phase 4]
Phase 4 study evaluating the clinical effectiveness of teriparatide after prior alendronate or risedronate therapy in postmenopausal osteopo…